Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Harrow (Nasdaq: HROW) announced it will release its fourth quarter and full-year 2025 financial results on March 2, 2026, after market close. A conference call and live webcast are scheduled for March 3, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. The company, a leading provider of ophthalmic disease management solutions, will also post a Letter to Stockholders on its website.
Harrow on track to double sales force, expand product reach By Investing.com
Harrow (NASDAQ:HROW) reaffirmed its 2025 revenue guidance of $270-280 million and announced significant expansion plans, including doubling its VEVYE sales force by Memorial Day and its surgical sales force for TRIESENCE. The company is also broadening its IHEEZO product reach and unifiying operations under the "OneHarrow" initiative. These developments come after a strong revenue growth of 47.83% over the last twelve months and analyst expectations of profitability this year.
Harrow on track to double sales force, expand product reach By Investing.com
Harrow (NASDAQ:HROW) reaffirmed its full-year 2025 revenue guidance of $270-280 million, alongside plans to double its VEVYE sales force by Memorial Day and expand its IHEEZO product to office settings. The company also announced the promotion of Patrick W. Sullivan to Chief Commercial Officer and successfully settled regulatory matters with the California Board of Pharmacy. These strategic moves and strong gross profit margin of 74.56% position Harrow for continued growth and market expansion.
HARROW INC (NASDAQ:HROW) Emerges as a High-Growth Momentum Stock with Strong Technical Setup
HARROW INC (NASDAQ:HROW) is identified as a high-growth momentum stock, showcasing strong fundamental growth with impressive earnings and sales increases, along with consistent positive estimate beats. Technically, the stock exhibits a top rating, trading above key moving averages, and a favorable setup pattern indicating potential for an upward move. This analysis suggests HROW is well-positioned for growth-focused investors and was found using a multi-layered screening method combining fundamental and technical indicators.
Harrow Completes Its Acquisition of Melt Pharmaceuticals
Harrow (Nasdaq: HROW) has completed its acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on non-opioid, non-IV sedation therapies. The acquisition aims to integrate Melt into Harrow's operations to expedite the NDA submission, approval, and market launch of MELT-300, a potential FDA-approved successor to MKO Melt used for ophthalmic procedures. Harrow plans to submit the New Drug Application for MELT-300 in 2027, with a U.S. commercial launch anticipated in 2028, and also intends to advance its MELT-210 drug candidate.
Harrow Announces Third Quarter 2025 Financial Results
Harrow announced strong third-quarter 2025 financial results, with total revenues increasing 45% year-over-year to $71.6 million and adjusted EBITDA of $22.7 million. The company enhanced its market position through strategic initiatives like expanding VEVYE® coverage, partnering with Alto Pharmacy for its VAFA program, and acquiring Melt Pharmaceuticals. Harrow also launched its "Harrow Access for All" program, aiming to improve patient access to its ophthalmic medications.
Advocate Group LLC Buys New Stake in Harrow, Inc. $HROW - MarketBeat
Advocate Group LLC has acquired a new stake in Harrow, Inc. (HROW) by purchasing 8,824 shares valued at approximately $269,000, indicating increasing institutional interest. Harrow's stock opened at $37.48, reflecting a 7.6% decrease, with significant volatility shown by its one-year range. Despite this, analysts maintain an optimistic outlook with a consensus "Buy" rating and a price target of $68.50.
Harrow Enters Agreement to Acquire Melt Pharmaceuticals
Harrow (Nasdaq: HROW) announced an agreement to acquire Melt Pharmaceuticals, a clinical-stage company developing non-opioid sedation therapies. Melt Pharmaceuticals was a former subsidiary of Harrow Health. The acquisition is subject to customary closing conditions, including approval by Melt stockholders.
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Harrow (Nasdaq: HROW) has announced a private offering of $250.0 million in senior unsecured notes due 2030 and a new $40.0 million revolving credit facility. The company plans to use the net proceeds to repay existing debt, including a facility with Oaktree Fund Administration and outstanding 2026 and 2027 Senior Notes, with any remaining funds for general corporate purposes. Harrow has also issued conditional redemption notices for its 2027 Notes and intends to do the same for its 2026 Notes upon the offering's closing, with both sets of notes to be delisted from Nasdaq.
Harrow, Inc. (HROW) Stock Analysis: A 76% Upside Potential In The Eye Of Investors
Harrow, Inc. (HROW), a pharmaceutical company specializing in ophthalmic products, is drawing investor attention with a $1.24 billion market cap and a strong "buy" consensus from analysts, predicting a 76.05% upside potential. While the company exhibits impressive revenue growth of 38.30% and a forward P/E of 14.72, it faces financial challenges including negative EPS and free cash flow, indicating a focus on reinvestment over immediate profitability. Technical indicators suggest the stock is nearing overbought territory, but a bullish MACD trend is noted, making it an attractive yet risky growth opportunity.
Harrow Health Q2 2025 slides: Mixed results amid strategic portfolio expansion
Harrow Health Inc. reported mixed results for Q2 2025, with consolidated revenue of $47.8 million but significant improvement in Adjusted EBITDA to $17.0 million. While VEVYE revenue declined, its prescription volume increased due to the "VEVYE Access For All" program, and IHEEZO saw strong growth after a "Retina Pivot." The company maintains its full-year 2025 revenue guidance of over $280 million, bolstered by strategic acquisitions and planned product launches.
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Samsung Bioepis has partnered with Harrow to commercialize its ophthalmology biosimilar portfolio, BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), in the United States. This agreement follows Biogen's decision to terminate its prior commercialization agreement with Samsung Bioepis, with Harrow assuming full responsibility for these products by the end of 2025. BYOOVIZ and OPUVIZ are biosimilars for LUCENTIS and EYLEA, respectively, designed to offer more accessible treatment options for various ophthalmic conditions.
PR News | On the Move: Career.io Names Klayman CMO - Wed., Jun. 18, 2025
Career.io has appointed Anna Klayman as its new CMO, where she will leverage her experience in scaling brands and customer acquisition to expand the company's presence. Harrow, an eyecare pharmaceutical company, named Mike Biega as VP of investor relations and communications. The American Society for Radiation Oncology (ASTRO) hired Karen Davis as its first VP of business development and marketing.
Harrow Health Q1 2025 slides: revenue up 43% as ophthalmic portfolio expands
Harrow Health Inc. reported Q1 2025 revenue of $47.8 million, a 43% increase year-over-year, driven by the expansion of its ophthalmic pharmaceutical portfolio and product launches like IHEEZO, VEVYE, and TRIESENCE. The company projects over $280 million in revenue for 2025, continuing its strong growth trajectory. Despite positive business developments, Harrow's stock saw a decline following the announcement, indicating investor concerns beyond the presented growth narrative.
Nordic Pharma launches authorized generic of Maxitrol
Nordic Pharma, Inc. is partnering with Harrow to commercially launch an authorized generic version of Maxitrol ophthalmic suspension in the U.S. This authorized generic offers patients a more affordable prescription option, being identical to the brand-name drug but sold under a different name by the original manufacturer. Maxitrol treats steroid-responsive inflammatory ocular conditions when bacterial infection or risk of infection exists, and its key ingredients are neomycin, polymyxin B sulfates, and dexamethasone.
VIDEO: Nordic, Harrow launch generic Maxitrol
Nordic Pharma and Harrow have partnered to launch an authorized generic version of Maxitrol, an ophthalmic suspension containing neomycin and polymyxin B sulfates and dexamethasone. This launch aims to provide a more cost-effective anti-infective and anti-inflammatory treatment option for patients. Nordic President Philip Gioia announced the launch in a Healio Video Perspective.
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
Harrow has expanded its VEVYE® Access for All (VAFA) program to include patients currently using ImprimisRx’s Klarity-C Drops®. This expansion allows over 25,000 Klarity-C patients to switch to FDA-approved VEVYE for $59 per bottle, eliminating access barriers like prior authorizations and offering free home delivery. The initiative aims to make dry eye treatment more affordable and accessible for patients, reducing administrative burdens for healthcare providers.
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for its drug TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL. This decision means TRIESENCE will be separately reimbursed outside of surgical bundled payments in Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) starting April 1, 2025, for three years. This approval significantly expands patient access to TRIESENCE, making it the only preservative-free synthetic corticosteroid with separate reimbursement in all traditional eyecare settings.
Harrow launches VEVYE accessibility program for patients
Harrow has introduced the "VEVYE Access for All" program to enhance the accessibility and affordability of its dry eye disease treatment, VEVYE. This initiative, operating through PhilRx, aims to simplify prescription processing, reduce patient costs to as low as $0 for initial prescriptions and $59 for refills, and offer a money-back guarantee. The program seeks to remove barriers to care by streamlining the prescribing and dispensing process for patients and eyecare professionals.
Harrow Inc reports results for the quarter ended in June - Earnings Summary
Harrow Inc reported an adjusted quarterly loss of 18 cents per share for the quarter ended in June, beating analyst expectations of a 20-cent loss. Revenue increased by 46.2% to $48.94 million, also surpassing analyst forecasts. The company's shares have seen significant growth this year, and analysts currently rate the stock as a "buy."
Harrow: Q4 Earnings Snapshot
Harrow, Inc. (HROW) reported a loss of $9.1 million in its fourth quarter, translating to 26 cents per share, or 27 cents adjusted. The pharmaceutical and drug compounding company generated $36.4 million in revenue for the quarter. For the full year, Harrow recorded a loss of $24.4 million on revenue of $130.2 million.
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
Harrow Health, Inc. announced a corporate name change to Harrow, Inc., effective immediately, to reflect its exclusive focus on eyecare pharmaceuticals as part of its five-year strategic plan. CEO Mark L. Baum stated that the name change aligns with the company's growing recognition in the ophthalmic community and its commitment to making ophthalmic products accessible and affordable. Harrow, Inc. is a leading U.S. eyecare pharmaceutical company specializing in the discovery, development, and commercialization of innovative ophthalmic products.
Harrow completes NDA transfer of Vigamox, launches product in US
Harrow announced it has completed the New Drug Application transfer for Vigamox, a fluoroquinolone antibiotic eye drop used to treat bacterial conjunctivitis, and will begin marketing and selling the product in the U.S. The company acquired exclusive U.S. commercial rights to Vigamox and four other FDA-approved ophthalmic products for $130 million in January. Harrow CEO Mark L. Baum highlighted Vigamox's established safety and efficacy, positioning it as a trusted treatment option for eye care professionals.
Harrow closes acquisition of U.S. rights to Novartis drugs
Harrow has completed its acquisition of exclusive U.S. commercial rights to five branded ophthalmic products from Novartis. This deal, valued at $130 million at closing with an additional milestone payment, is expected to be immediately financially accretive to Harrow, reaffirming its 2023 revenue guidance. The acquisition positions Harrow among leaders in the U.S. ophthalmic pharmaceuticals market, offering more treatment options and flexibility to its customers.
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
Harrow announced the availability of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) formulations for in-office use from its ImprimisRx 503B outsourcing facility. These patent-pending, refrigeration-stable, fortified antibiotic solutions are now available to eyecare professionals for immediate treatment of patients, with a patient access program and replacement guarantee. Eyecare professionals and surgeons like Dr. Eric Donnenfeld, Dr. Brian Shafer, and Dr. Terrence O’Brien commented on the game-changing nature of having these formulations readily available for sight-threatening infections.
Harrow to acquire US rights to 5 ophthalmic products from Novartis
Harrow announced its acquisition of exclusive U.S. commercial rights for five FDA-approved ophthalmic products from Novartis, marking their second transaction in the last year. This deal, valued at up to $175 million, significantly strengthens Harrow's presence in the U.S. ophthalmic pharmaceutical market. Novartis will transfer all net profits to Harrow during a 6-month non-disclosure agreement period before Harrow takes full control of sales and manufacturing.
Harrow Secures Capital to Close Recently Announced Acquisition
Harrow Health, Inc. announced the pricing of a $35 million offering of 11.875% senior notes due 2027 to fund a previously announced acquisition. The notes received a "BB" rating from Egan‑Jones Ratings Company and are expected to be listed on the Nasdaq Global Market under "HROWM." The company plans to use the proceeds, along with cash on hand and a secured loan facility, for the acquisition and general corporate purposes.
Harrow agrees to acquire US rights to Novartis’ ophthalmic products
Harrow has signed a binding agreement to acquire exclusive US commercial rights to five ophthalmic products from Novartis for a payment of $130m at closing, with an additional $45m milestone payment possible. The acquired products, including Ilevro, Vigamox, Maxidex, Nevanac, and Triesence, are FDA-approved and are expected to broaden Harrow's pharmaceutical portfolio in the ophthalmic surgical and acute care markets. Novartis will continue to market these products in the US during a six-month NDA transfer period before Harrow takes over full operations.
Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products
Harrow Health has acquired the exclusive U.S. commercial rights to five FDA-approved ophthalmic products from Novartis for $130 million, with a potential additional $45 million milestone payment. This acquisition is expected to expand Harrow's pharmaceutical portfolio and generate 2023 net revenues of $135-$143 million and adjusted EBITDA of $44-$50 million. To fund a portion of the purchase, Harrow initiated a public offering of senior notes and shares.
Harrow Sells Non-Ophthalmic Compounding Business
Harrow has sold its non-ophthalmic compounding business to Innovation Compounding Pharmacy, an affiliate of Revelation Pharma Corporation. This transaction aligns with Harrow's strategy to focus exclusively on ophthalmic pharmaceuticals. The company plans to use the proceeds to expand its branded ophthalmic product portfolio.
